Trial Profile
Study of the modulatory activity of an LHRH [luteinising hormone-releasing hormone] agonist (leuprolide) [leuprorelin] on melanoma peptide vaccines [melanoma vaccine gp100 + melanoma vaccine] as adjuvant therapy in melanoma patients.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Leuprorelin (Primary) ; MAGE-A3 peptide vaccine; Melanoma vaccine; Melanoma vaccine gp100
- Indications Malignant melanoma
- Focus Therapeutic Use
- 01 Oct 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 09 May 2011 Planned end date changed from 1 Dec 2011 to 1 Dec 2012 as reported by ClinicalTrials.gov.
- 27 Sep 2010 Planned end date changed from 1 Dec 2009 to 1 Dec 2011 as reported by ClinicalTrials.gov.